Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

An innovative study, co-designed by Aboriginal Women, has led to remission of type 2 diabetes. The research described and ...

A new bill in Arkansas is the first on a state level to try and stem the “migration” of coverage for continuous glucose monitors to a pharmacy-only benefit.

Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

Much progress has been made in diabetes technology over the past decade. Continuous glucose monitoring has achieved high accuracy and reliability, resulting ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually controlled, while hybrid ...

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

West Pharmaceutical Services Inc.'s stock tumbled 33% Thursday, to lead S&P 500 decliners, after the manufacturer of injectable-pharmaceutical packaging and delivery systems offered guidance for 2025 ...